Landmark study in cell introduces first-of-its-kind optogenetic screening platform for drug discovery
REDWOOD CITY, CA — July 14, 2025 — A landmark study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by scientists at Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases. The new peer-reviewed publication demonstrates the platform’s capabilities by applying it to the integrated stress response (ISR), a key aging- and disease-associated signaling pathway implicated in neurodegeneration, cancer and viral infection.
In the Cell study, Integrated Biosciences scientists used optogenetic control to selectively activate the ...